Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM)

Autor:	Sanjay K. Aggarwal, Andromachi Giannopoulou, Andrzej Jakubowiak, Rafael Fonseca, Marco Campioni, Sumeet Panjabi, Ivan Houisse, Agnes Benedict
Rok vydání:	2016
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Refractory Multiple Myeloma Carfilzomib chemistry.chemical_compound chemistry Quality of life Internal medicine medicine In patient Progression-free survival business Dexamethasone Lenalidomide medicine.drug
Zdroj:	Journal of Clinical Oncology. 34:8021-8021
ISSN:	1527-7755 0732-183X
Popis:	8021Background: In ASPIRE, KRd achieved superior progression free survival (PFS) (HR = 0.69; p = 0.0001) and improved quality of life (QoL) (p < 0.001) over Rd in patients (pts) with R/RMM. We asse...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::11c11e4413554cd211066605e6f43ec5 https://doi.org/10.1200/jco.2016.34.15_suppl.8021 Zobrazit plný text záznamu